EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience

Giosiana Bosco, Francesco Di Giacomo Barbagallo, Maurizio Di Marco, Sabrina Scilletta, Nicoletta Miano, Stefano Esposto, Giovanni Pennisi, Simone Prezzavento, Antonio Gallo, Ernestina Marianna De Francesco, Roberta Malaguarnera, Antonino Di Pino und 3 weitere

Progress in Cardiovascular Diseases · 2025

DOI: 10.1016/j.pcad.2025.05.008 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Progress in Cardiovascular Diseases, 2025. Verfasst von Giosiana Bosco und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; Department of Medicine and Surgery, "Kore" University of Enn…. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type II, Cholesterol, LDL, Vascular Stiffness, RNAi Therapeutics. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università di Catania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: Familial hypercholesterolemia (FH) is characterized by elevated LDL-C and an increased risk of premature cardiovascular events. Inclisiran is a small interfering RNA that inhibits hepatic PCSK9 synthesis and promotes LDL-C clearance by enhancing LDLR expression on hepatocytes. This study aimed to evaluate the efficacy of six-months add-on inclisiran on lipid profile and PWV in FH; furthermore, we investigated the association between LDL-C reduction and PWV variation. METHODS: This prospective observational study involved 78 genetically confirmed FH subjects with an LDL-C off-target despite high-intensity statins plus ezetimibe. All subjects obtained biochemical analysis and PWV evaluation at baseline and after six months add-on inclisiran. RESULTS: After six months add-on inclisiran, 41 % of subjects achieved LDL-C targets. Significant reductions of LDL-C (-41.5 %, p < 0.001), ApoB (-33.7 %, p < 0.01), Non-HDL-C (-35.9 %, p < 0.001), and Lp(a) (-18 %, p < 0.01) were observed, while PWV improved by 14.4 % (p < 0.001). In a secondary analysis, the Primary prevention group showed a higher prevalence of subjects on LDL-C target than the Secondary prevention group (59 % vs 23.1 %, p < 0.001). Both groups exhibited significant improvements of lipid profile and PWV (Δ - 14.1 %, p < 0.01 and Δ - 14.6 %, p < 0.001, respectively). Linear regression showed a significant association between ΔPWV and ΔLDL-C in the whole study population as well as in the Primary and Secondary prevention groups (p for all

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperlipoproteinemia Type IICholesterol, LDLVascular StiffnessRNAi TherapeuticsPCSK9 InhibitorsHumansMaleFemaleMiddle AgedProspective StudiesAdultTreatment OutcomeBiomarkersTime FactorsPulse Wave AnalysisProprotein Convertase 9Anticholesteremic AgentsRNA, Small Interfering

Stichwörter der Autor:innen

Familial hypercholesterolemiaLDL cholesterolPulse wave velocitySmall interfering RNA

Substanzen

Cholesterol, LDLBiomarkersPCSK9 protein, humanProprotein Convertase 9ALN-PCSPCSK9 InhibitorsAnticholesteremic AgentsRNA, Small Interfering

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy; Department of Medicine and Surgery, "Kore" University of Enna, Enna, Italy.
  • Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
  • Sorbonne Université, INSERM UMR1166, Lipidology and Cardiovascular Prevention Unit, Department of Nutrition, APHP, Hôpital Pitié-Salpètriêre, 47/83 Boulevard de L'Hôpital, 75013 Paris, France.
  • Department of Medicine and Surgery, "Kore" University of Enna, Enna, Italy.
  • Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. Electronic address: spiro@unict.it.

Förderung

  • Università di Catania

Zitieren

APA

Bosco, G., Di Giacomo Barbagallo, F., Di Marco, M., Scilletta, S., Miano, N., Esposto, S., Pennisi, G., Prezzavento, S., Gallo, A., De Francesco, E. M., Malaguarnera, R., Di Pino, A., Purrello, F., Piro, S., & Scicali, R. (2025). Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2025.05.008

Vancouver

Bosco G, Di Giacomo Barbagallo F, Di Marco M, Scilletta S, Miano N, Esposto S, et al. Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience. Progress in Cardiovascular Diseases. 2025. doi:10.1016/j.pcad.2025.05.008

BibTeX
@article{Bosco2025,
  author = {Bosco, Giosiana and Di Giacomo Barbagallo, Francesco and Di Marco, Maurizio and Scilletta, Sabrina and Miano, Nicoletta and Esposto, Stefano and Pennisi, Giovanni and Prezzavento, Simone and Gallo, Antonio and De Francesco, Ernestina Marianna and Malaguarnera, Roberta and Di Pino, Antonino and Purrello, Francesco and Piro, Salvatore and Scicali, Roberto},
  title = {Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience},
  journal = {Progress in Cardiovascular Diseases},
  year = {2025},
  doi = {10.1016/j.pcad.2025.05.008}
}
Kostenlos starten →